The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea

Noh, Hyeon-seok; Jang, Jeongju; Kwon, Seungwon; Cho, Seung‐Yeon; Jung, Woo Sang; Moon, Sang Kwan; Park, Sungha; Ko, Chang Nam; Kim, Ho; Park, Seong-Uk

doi:10.3390/jcm9082422

Cited by 6 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective cohort study in South Korea by Noh et al. ( 52 ) compared conventional treatment and combination treatment for IBD and found a reduced risk of PD in the combined treatment group without normal controls, because of which it was excluded. Paakinaho et al.’s study ( 23 ) examined the association between RA and PD by improving anti-rheumatic drugs, which did not match the data of this study; thus, it was excluded from the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

The association between Parkinson’s disease and autoimmune diseases: A systematic review and meta-analysis

Wan

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disorder that frequently occurs in the older population. Previous epidemiological studies have suggested an association between PD and autoimmune diseases (AIDs). However, some studies have shown conflicting results. This study aimed to summarize existing epidemiological studies on the association between PD with AIDs and to conduct a meta-analysis of combinable results. Four electronic databases (PubMed, Embase, Web of Science Core Collection, and MEDLINE) were searched from each database’s inception date until December 12, 2022. All studies that explored the relationship between PD and AIDs were included for quantitative analysis and qualitative review. The pooled relative risk with 95% confidence intervals (CIs) was calculated using a random or fixed effects model. A total of 46 observational studies involving 873,643 patients and 13,402,821 controls were included; ultimately, 38 studies were included in the meta-analysis. The risk of PD combined with AIDs was significantly higher (odds ratio [OR]=1.55, 95% CI: 1.33–1.81), and subgroup analysis found no significant differences in risk by study type, gender, age, and race. Regarding the AID types, the results showed an increased risk of PD combined with bullous pemphigoid (OR=2.67, 95% CI: 2.15–3.31), inflammatory bowel disease (OR=1.30, 95% CI: 1.18–1.45), Crohn’s disease (OR=1.30, 95% CI: 1.20–1.42), ulcerative colitis (OR=1.31, 95% CI: 1.14–1.50), Sjögren’s syndrome (OR=1.61, 95% CI: 1.24–2.09), and Graves’ disease (OR=1.45, 95% CI: 1.24–1.70) than controls. However, there appeared to be no significant association between PD and systemic lupus erythematosus (OR=0.82, 95% CI: 0.66–1.03), multiple sclerosis (OR=2.02, 95% CI: 0.87–4.70), rheumatoid arthritis (OR=0.79, 95% CI: 0.61–1.03), or celiac disease (OR=1.16, 95% CI: 0.79–1.69). This study supports the existence of a strong link between AIDs and PD. When PD and AIDs are identified, clinicians need to be aware of the possibility of coexistence. However, there are some limitations of this study, such as the apparent heterogeneity of some of the results and the fact that most of the included study types were retrospective. Therefore, future larger prospective cohort studies are needed to further explore the interaction between PD and AIDs.Systematic review registrationINPLASY, identifier INPLASY202280088.

show abstract

Section: Resultsmentioning

confidence: 99%

The association between Parkinson’s disease and autoimmune diseases: A systematic review and meta-analysis

Wan

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In the pathogenesis of IBD and PD, there are some similar pro-inflammatory factors in the inflammatory process of both diseases, such as TNF-α and IL-1β. Dopaminergic degeneration of central substantia nigra striatum with intestinal inflammation is related to the increase of TNF-α and IL-1β ( 47 ). Peter et al ( 14 ) reported an interesting American cohort study that the incidence rate of PD in patients with IBD treated with anti-TNF was reduced by 78% compared with those without exposure, which supported the role of systemic inflammation in the pathogenesis of both IBD and PD.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals

Zhang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundThe relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis.MethodsSearch the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs).ResultsIn total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03–1.33, P = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, P = 0.311) for Crohn’s disease (CD), and 1.18 (95% CI: 1.06, 1.31, P = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06–1.41, P = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58–2.41, P = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, P = 0.126).ConclusionOur results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old.

show abstract

“…IBD was defined as the presence of a major or minor diagnostic code associated with ICD-10 code K50 for CD or ICD-10 code K51 for UC, with special V codes (V130 for CD and V131 for UC) provided by the Rare Intractable Diseases (RID) programme, which is part of the NHIS [ 18 ]. In Korea, the RID programme provides a copayment reduction of approximately 10% for various rare and intractable diseases including IBD.…”

Section: Methodsmentioning

confidence: 99%

Increased bronchiectasis risk and related risk factors in inflammatory bowel disease: a 10-year Korean national cohort study

Lee,

Yang,

Shin

et al. 2024

ERJ Open Res

View full text Add to dashboard Cite

BackgroundThe association between inflammatory bowel disease (IBD) and an increased risk of bronchiectasis, as well as contributing factors, remains unclear. Additionally, whether bronchiectasis increases disease burden in IBD remains unknown. Therefore, this study aimed to 1) assess whether IBD increases the risk of incident bronchiectasis; 2) compare the risk of bronchiectasis between individuals with Crohn's disease (CD) and those with ulcerative colitis (UC); 3) identify risk factors for bronchiectasis in individuals with IBD; and 4) examine the disease burden in individuals with IBD and bronchiectasisversusthose without.MethodsWe conducted a population-based matched cohort study involving adults aged ≥20 years with IBD, using data acquired from the National Health Insurance Service-National Sample Cohort database in Korea between 2002 and 2012.ResultsDuring the mean follow-up of 9.6 years, the incidence rate of bronchiectasis was 419.63/100 000 and 309.65/100 000 person-years (PY) in the IBD and matched cohorts (adjusted hazard ratio [aHR]=1.21, 95% confidence interval [CI]=1.05–1.39), respectively. UC was associated with increased bronchiectasis risk (aHR=1.42, 95% CI=1.19–1.69), while CD was not. Multivariate Cox regression analyses showed that age, male sex, medical aid, underweight status, chronic obstructive pulmonary disease, and diabetes mellitus were associated with an increased risk of bronchiectasis in the IBD cohort (p<0.05). The mortality, emergency department visit, and hospitalisation rates were significantly higher for individuals with IBD and bronchiectasis compared to those without bronchiectasis (p<0.05).ConclusionIBD is associated with increased risk of bronchiectasis, which results in a greater disease burden in individuals with IBD.

show abstract

The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea

Cited by 6 publications

References 38 publications

The association between Parkinson’s disease and autoimmune diseases: A systematic review and meta-analysis

The association between Parkinson’s disease and autoimmune diseases: A systematic review and meta-analysis

Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals

Increased bronchiectasis risk and related risk factors in inflammatory bowel disease: a 10-year Korean national cohort study

Contact Info

Product

Resources

About